港股異動 | 君實生物(1877.HK)漲超4% 新冠雙抗體療法獲美國FDA緊急使用授權
格隆匯2月10日丨君實生物(1877.HK)漲超4%,報86.05港元,盤中高見88.95港元;君實生物(688180.SH)亦漲6.74%,報100.11元。君實生物今日午間宣佈,美國食品藥品監督管理局(“FDA”)已批准美國禮來製藥公司在研抗體藥物Etesevimab (JS016/LY-CoV016) 1,400 mg及Bamlanivimab (LY-CoV555) 700 mg雙抗體療法緊急使用授權。該療法被授予用於治療伴有進展為重度COVID-19及╱或住院風險的12歲及以上輕中度COVID-19患者。患者在確診COVID-19並在出現症狀後10天內應該儘快通過單次靜脈注射進行Etesevimab和Bamlanivimab雙抗體治療。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.